NCT00178854

Risperidone (Risperdal) Augmentation in Depressed Partial Responders to SRI Treatment

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Vanderbilt University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

This is a study of the chemistry of depression in people who are taking an antidepressant but it is not working well. The changes in brain chemicals that occur when an SSRI type antidepressant is supplemented with risperidone (Risperdal®) will be studied. Spinal fluid is used to measure chemical levels of dopamine, serotonin, and other chemicals thought to be involved in depression. The study has potential to help understand and treat depression.

Conditions

• Treatment Resistant Depression

Interventions

Type	Name	Description
DRUG	Risperidone

Timeline

• Start date: 2004-05-01
• Primary completion: 2006-03-01
• Completion: 2006-03-01
• First posted: 2005-09-15
• Last updated: 2017-04-04

Locations

1 site across 1 country: United States